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FOXP2, the first gene to have been implicated in a developmental communication disorder, offers a unique entry
point into neuromolecular mechanisms influencing human speech and language acquisition. In multiple members
of the well-studied KE family, a heterozygous missense mutation in FOXP2 causes problems in sequencing muscle
movements required for articulating speech (developmental verbal dyspraxia), accompanied by wider deficits in
linguistic and grammatical processing. Chromosomal rearrangements involving this locus have also been identified.
Analyses of FOXP2 coding sequence in typical forms of specific language impairment (SLI), autism, and dyslexia
have not uncovered any etiological variants. However, no previous study has performed mutation screening of
children with a primary diagnosis of verbal dyspraxia, the most overt feature of the disorder in affected members
of the KE family. Here, we report investigations of the entire coding region of FOXP2, including alternatively
spliced exons, in 49 probands affected with verbal dyspraxia. We detected variants that alter FOXP2 protein
sequence in three probands. One such variant is a heterozygous nonsense mutation that yields a dramatically
truncated protein product and cosegregates with speech and language difficulties in the proband, his affected sibling,
and their mother. Our discovery of the first nonsense mutation in FOXP2 now opens the door for detailed inves-
tigations of neurodevelopment in people carrying different etiological variants of the gene. This endeavor will be
crucial for gaining insight into the role of FOXP2 in human cognition.
The FOXP2 gene (MIM 605317) has been implicated
in a severe form of speech and language disorder (SPCH1
[MIM 602081]) found in a large multigenerational ped-
igree and in an independent chromosome translocation
case (Lai et al. 2001). This discovery has had an impact
on a range of fields, including genetics, neuroscience,
clinical neurology, and evolutionary anthropology (for
reviews, see Fisher et al. 2003; Marcus and Fisher 2003;
Vargha-Khadem et al. 2005). FOXP2, located in band
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7q31, encodes a transcription factor, containing poly-
glutamine tracts, a zinc finger, a leucine zipper motif,
and a forkhead-box DNA-binding domain (Lai et al.
2001; Wang et al. 2003), and it is likely to regulate gene
expression in defined areas of developing lung, cardio-
vascular, intestinal, and neural tissue (Shu et al. 2001;
Lai et al. 2003). The available expression data are com-
patible with a conserved role (or roles) for this gene in
regulating development of neural circuitry underlying
motor control and sensory-motor integration in mam-
mals and birds (Ferland et al. 2003; Lai et al. 2003;
Takahashi et al. 2003; Haesler et al. 2004; Teramitsu et
al. 2004). Notwithstanding the high conservation of
FoxP2 gene sequences and expression patterns in the
different vertebrate species studied thus far, evolutionary
analyses have demonstrated that the human version of
the gene has been subject to positive selection within the
past 200,000 years (Enard et al. 2002; Zhang et al.
2002). Thus, the relevant neurogenetic pathways may
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have undergone human-specific modifications at a time
when spoken language was emerging (Enard et al. 2002;
Zhang et al. 2002), although the precise nature of the
putative mechanisms has yet to be determined.
FOXP2 represents a unique molecular entry point in-
to the investigation of neuronal processes involved in
speech and language. However, there has been consid-
erable debate over whether sequence variation in this
gene might have significance beyond the unusual case of
the KE family. In this three-generation pedigree, a het-
erozygous missense mutation (Lai et al. 2001) cosegre-
gates with deficits in sequencing the complex, coordi-
nated orofacial movements required for speech (verbal
dyspraxia), accompanied by a wide range of linguistic
and grammatical deficits (Vargha-Khadem et al. 1998;
Watkins et al. 2002). The mutation results in an argi-
nine-to-histidine substitution (R553H) at a highly con-
served residue within the DNA-binding domain (Lai et
al. 2001). In vitro studies of the corresponding substi-
tution in another forkhead-box protein (R127H in hu-
man FOXC1) suggest that the change can dramatically
interfere with DNA-binding and transactivation capac-
ity (Saleem et al. 2003), although this has not yet been
demonstrated for FOXP2 itself. The FOXP2 locus has
also been found to be directly disrupted in an indepen-
dent case of speech and language disorder (CS) associ-
ated with a de novo balanced translocation involving
chromosomes 7 and 5 (Lai et al. 2001).
Following identification of the KE family mutation
and CS translocation, many studies have carried out tar-
geted linkage/association analyses of the 7q region or
mutation screening of FOXP2 in children with language-
related disorders, including specific language impairment
(SLI [MIM 606711]), autism (MIM 608636), and dys-
lexia (MIM 604254) (e.g., Newbury et al. 2002; Wassink
et al. 2002; Gauthier et al. 2003; Kaminen et al. 2003;
O’Brien et al. 2003). Despite such efforts, the missense
mutation of the KE family remains the single reported
case of an unambiguous etiological variant in FOXP2
coding sequence in the literature. This places limits on
what can be learned about the influences of FOXP2 on
human brain development, since, up to this point, all
the relevant neuropsychological and neuroimaging in-
vestigations have necessarily been limited to just this one
allelic variant (Vargha-Khadem et al. 1998; Watkins et
al. 2002; Belton et al. 2003; Lie´geois et al. 2003) or to
gross chromosomal rearrangements that may involve ef-
fects of multiple additional genes (Lie´geois et al. 2001).
Our current investigation was driven by the obser-
vation that, to date, no study had fully examined the
sequence of FOXP2 in children with a phenotypic profile
which closely corresponds to that found in the KE family
(or to that found in cases of chromosomal abnormality
involving FOXP2). Although a broad range of language-
related deficits are evident in these individuals, the most
overt symptom of their disorder is a severe develop-
mental verbal dyspraxia, and it is this feature that pro-
vides the most reliable indicator of affection status (Var-
gha-Khadem et al. 1998; Lie´geois et al. 2001; Watkins
et al. 2002). Notably, previous screening studies of the
entire FOXP2 ORF have focused on individuals affected
with typical SLI, autism, or dyslexia (Newbury et al.
2002; Wassink et al. 2002; Gauthier et al. 2003; Ka-
minen et al. 2003). Verbal dyspraxia might indeed be
present in a subset of such children, but it is not generally
considered to be a core feature for any of these devel-
opmental disorders (World Health Organization 1993;
American Psychiatric Association 1994) and may rep-
resent the defining symptom of a distinctive clinical en-
tity (or entities) (Lewis et al. 2004). Given that FOXP2
was the first known case of a gene to be implicated in
impaired speech and language acquisition, it was ap-
propriate for these previous investigations to assess its
possible involvement in a variety of language-related dis-
orders. Nevertheless, for the present study, we hypoth-
esized that we might maximize the possibility of de-
tecting further etiological variants by screening, for the
first time, a panel of patients with a primary diagnosis
of verbal dyspraxia.
After the publication by Lai et al. (2001), our de-
partment received many referrals of cases with unex-
plained speech and language deficits, requesting testing
for FOXP2 abnormalities. To more closely match the
phenotype of the KE family, patients were selected for
FOXP2 screening only if they fulfilled the following
criteria: presence of speech articulation problems diag-
nosed by a clinician (e.g., a pediatrician or neurologist),
normal karyotype, absence of mental retardation and
congenital abnormalities, normal hearing, and no other
medical/genetic diagnosis. The study was approved by
the Oxfordshire Clinical Research Ethics Committee. Pa-
tients were enrolled sequentially, with no preference
given to those with a family history of language disorder.
The referring doctors and parents filled in a question-
naire for the study, which contained confirmation of the
phenotype and provided results of the karyotype, speech
examination report, and family history. DNA samples
were collected from 49 probands, of whom 10 had one
(or more) affected siblings whose samples were also in-
cluded in the study. All affected cases were white, were
within the 4–12-year-old age group (except for one pair
of siblings aged 30 and 33 years), and resided in Europe,
Australia, or the United States.
We conducted mutation screening across all FOXP2
exons identified by Lai et al. (2001) via denaturing
high-performance liquid chromatography (DHPLC), fol-
lowed by direct sequencing of fragments showing variant
elution patterns, using identical protocols and primers
to those described elsewhere by Newbury et al. (2002).
We similarly analyzed additional alternatively spliced
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and 5′ UTR exons reported by Bruce and Margolis
(2002) (see table A1 for sequences of all primers). All
assays spanned entire exons, plus short stretches of
flanking intronic sequence. Screening of our cohort of
49 probands revealed two 5′ UTR variants and six in-
tronic changes (fig. 1). Five of these changes correspond
to polymorphisms reported in earlier studies of FOXP2
(Newbury et al. 2002), and two overlap with SNPs
that are present in public databases (rs17137124
and rs10227893). In support of the sensitivity of our
DHPLC-based approach, the public databases contain
no other validated SNPs in the regions of FOXP2 in-
vestigated in this study.
Our screening of probands also identified three novel
exonic allelic variants in the coding region, each of which
is predicted to yield a change in FOXP2 protein sequence
(fig. 1). Crucially, one of these coding changes was a
heterozygous CrT transition in exon 7, yielding a stop
codon at position 328 of the FOXP2 protein (R328X)
(fig. 2). We directly sequenced exon 7 in 252 control
chromosomes from Human Random Control panels
(obtained from the European Collection of Cell Cultures
[ECACC]) but did not detect any sequence alterations,
indicating that the change observed in the proband is
unlikely to represent a polymorphism, according to cri-
teria suggested by Collins and Schwartz (2002). More-
over, this nonsense mutation was also found in the af-
fected sibling of the proband, as well as their mother,
who was known to have a history of speech problems,
and it was absent in their father, who has normal speech.
The R328X mutation is highly likely to have functional
significance, since it leads to dramatic truncation of the
predicted product, yielding a FOXP2 protein lacking
critical functional domains—including the zinc-finger
and leucine zipper, which mediate dimerization (Wang
et al. 2003), and the characteristic forkhead DNA-bind-
ing domain, known to be critical for transcription factor
function (fig. 2). It is also possible that this mutation
could lead to nonsense-mediated mRNA decay of tran-
scripts from the mutant allele.
The two remaining coding changes that we identified
were a heterozygous ArT transversion in exon 2 in one
proband, and a heterozygous insertion of the sequence
CAGCAGCAACAA into the polyglutamine-encoding
region of exon 5 in another. At the amino acid level,
these changes are predicted to yield a glutamine-to-leu-
cine change at residue 17 (Q17L) and a polyglutamine-
tract expansion from 40 to 44 consecutive glutamines,
respectively (fig. 2). Neither change was detected in
screening of large numbers of chromosomes from
Human Random Control panels (366 chromosomes
screened for the Q17L change and 228 chromosomes
screened for the polyglutamine expansion). However, in
each case, the proband had a sibling who was diagnosed
as affected but did not carry the relevant coding change.
In addition, on the basis of current data and analyses
of protein function using in silico methods (Ng and Hen-
ikoff 2001; Ramensky et al. 2002), it is not clear what
the potential functional consequences of a Q17L change
in FOXP2 might be. The substitution site lies in a region
of unknown function close to the N-terminus of the
protein but is conserved in the FOXP2 orthologues of
all species thus far studied, including birds, rodents, and
primates (Enard et al. 2002; Zhang et al. 2002; Webb
and Zhang 2005), as well as in the closely related pro-
teins FOXP1 and FOXP4 (Teufel et al. 2003). With re-
gard to the polyglutamine change, although Wassink et
al. (2002) previously detected small internal deletions in
the Q40 tract in two families with autism, our study
represents the first report of an expansion of this region
in any individual. Newbury et al. (2002) previously iden-
tified a potential insertion of two CAGs within the
smaller (Q10 ) tract in a family with SLI, but this did not
cosegregate with the disorder, and its location in a re-
petitive region at the intron/exon border of exon 6 sug-
gested that it would not have any impact on FOXP2
protein sequence. The expansion from 40 to 44 residues
of the longer FOXP2 polyglutamine tract in our proband
with verbal dyspraxia is outside the normal intraspecies
range observed for FOXP2 orthologues; the number of
consecutive glutamines in the corresponding region in
other species varies from 38 glutamines (in zebra finch,
chicken, and gorilla) to a maximum of 41 glutamines
(in chimpanzee) (Enard et al. 2002; Zhang et al. 2002;
Webb and Zhang 2005).
Our discovery of an R328X variant cosegregating
with speech deficits in a multiplex family gives an op-
portunity to compare the neurodevelopmental conse-
quences of a FOXP2 nonsense mutation to those of the
missense mutation in the KE family. Recent clinical eval-
uation of cases carrying the R328X mutation suggests
a similar phenotype to that associated with the R553H
mutation of the KE family, where prominent difficulties
in speech articulation are accompanied by more general
problems with expressive and receptive language. The
development of the children carrying the R328X mu-
tation was assessed using the Griffiths (1970) Mental
Development Scales, which evaluate overall devel-
opment from birth to 8 years of age in six domains
(“Locomotor,” “Personal and Social,” “Hearing and
Speech,” “Eye/Hand Coordination,” “Performance,” and
“Practical Reasoning”), while the Preschool Language
Scale-3 (Zimmerman et al. 1992) was used to formally
measure receptive and expressive language skills. As-
sessment of the proband when he was 4 years old in-
dicated developmental delays in the domains of speech
and language, and social skills. He communicated
mainly using single words and was unable to repeat mul-
tisyllabic words. Eye-hand coordination was satisfac-
tory, but he had difficulty with activities in the Practical
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Figure 2 A, Amino acid sequence of main isoform of human FOXP2, showing all coding changes found thus far in individuals with
developmental verbal dyspraxia (Lai et al. 2001; present study). Each change was absent from large numbers of control chromosomes, but only
the R328X and R553H mutations are found in multiple affected members in families segregating developmental speech and language disorder.
B, Nucleotide sequence of normal and expanded polyglutamine-encoding region identified in one of the probands in this study.
Reasoning domain. His receptive and expressive lan-
guage scores were 55 and 54, respectively (mean stan-
dard score is 100, with an SD of 15; scores between 85
and 115 are considered within normal limits). Thus, his
language skills were almost 3 standard deviations below
the normative mean, equivalent to that of a child of 2
years 6 mo (∼18 mo below chronological age). During
informal assessment of articulation, he had difficulty in
producing consonants at the beginning of words and
became frustrated and significantly less intelligible dur-
ing word repetition.
His younger sister has a history of motor and oro-
pharyngeal dyspraxia, otitis media, and oesophageal re-
flux. On assessment using the Griffith Scales, at age 1
year 8 mo, she showed her poorest performance in the
Hearing and Speech domain. She did not speak any
words and could not identify objects, and her vocali-
zation was poor. However, she was interested in puzzle-
type toys and was able to put different shapes into form
boards; her general motor skills at this age appeared
normal. When she was subsequently assessed on the Pre-
school Language Scale-3 , at the age of 2 years and 11
mo, her receptive and expressive language scores were
71 and 73, respectively. Both scores were almost 2 stan-
dard deviations below the normative mean and were
equivalent to the performance of an 11-mo-old child
(i.e., 2 years below chronological age).
The mother, who also carried the R328X mutation,
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reported a history of speech delay in childhood. At pre-
sent, she has severe problems with communication. She
volunteered to bring a relative to the consultations, be-
cause she could not understand the nuances of what was
said and was afraid of misinterpretation. She had poor
speech clarity and very simple grammatical construc-
tions. Her speech had less varied cadence than most
people’s, but her vocabulary was satisfactory. Her re-
ceptive difficulties were compounded by performance
anxiety. Formal speech and language assessment has
been offered to her and will be reported separately.
Overall, the data from our screening of cases with
verbal dyspraxia support a number of important con-
clusions. First, the evidence indicates that one of the
coding changes detected in our patients (R328X) is of
direct etiological significance, since it was not found in
a large panel of control chromosomes, it cosegregates
with the disorder in all three affected members of a mul-
tiplex family, and it is a nonsense mutation that yields
a substantially truncated protein lacking key functional
domains. Thus, this is the first report of an independent
causative point mutation in FOXP2 following the iden-
tification of the KE mutation by Lai et al. (2001), and
the only known case of a nonsense mutation in this gene.
The other coding changes (Q17L and Q40rQ44), al-
though similarly undetected in control chromosomes,
were only found in probands, and so functional studies
will be important to assess whether they have any impact
on the behavior of FOXP2. Second, screening of FOXP2
in !50 probands diagnosed on the basis of develop-
mental verbal dyspraxia yielded a much higher fre-
quency of protein sequence changes (∼6.1%) than that
previously found by studying the entire coding region
in children with typical SLI (no unambiguous coding
mutations in 43 probands) or with autism (!0.8%; two
heterozygous poly-Q deletions in a total of 239 families)
(Newbury et al. 2002; Wassink et al. 2002; Gauthier et
al. 2003). The frequency of unequivocal etiological var-
iants in our sample was ∼2%. It is worth reiterating that
we did not make familial clustering of the disorder a
requirement when ascertaining our sample. These data
suggest that a re-evaluation of the relevance of FOXP2
for common cases of neurodevelopmental disorder is
warranted, and that additional coding changes might be
identified in individuals with an appropriate phenotypic
profile. The situation could be comparable to that found
for telomere abnormalities in idiopathic mental retar-
dation, where the former account for a small (5.1%) but
significant proportion of the many individuals affected
with the disorder (Flint and Knight 2003). Third, our
data caution against drawing conclusions about the in-
fluence of FOXP2 from limited mutation searches that
screen only small regions of the FOXP2 coding region,
such as that encoding the forkhead domain (see, e.g.,
O’Brien et al. 2003)—especially given that nonsense mu-
tations, like the one identified here, might lie far from
known functional domains but still have major conse-
quences for protein function. Fourth, the observation of
a heterozygous nonsense mutation that severely trun-
cates FOXP2 in multiple cases with developmental ver-
bal dyspraxia, gives independent support to the hypoth-
esis that FOXP2-related disorder may result from a
mechanism of reduced functional gene dosage in the de-
veloping CNS.
In conclusion, the present study indicates that, whereas
the neurodevelopmental consequences of FOXP2 disrup-
tion are complex, involving impairment of both speech
and language skills, the presence of verbal dyspraxia is
a key clinical aspect that identifies children most suitable
for FOXP2 mutation screening. The identification of an
unambiguous causative mutation in a cohort of !50 pro-
bands (without prior selection for familial transmission)
suggests that other etiological variants may be discov-
ered in the future. Finally, the development of individuals
carrying the R328X nonsense mutation can now be as-
sessed using neuropsychological tests and neuroimaging
paradigms identical to those employed for the intensive
studies of the KE family conducted over the past 15 years
(see, e.g., Watkins et al. 2002; Belton et al. 2003; Lie´-
geois et al. 2003). Therefore, our work opens the door
for the future integration of behavioral and neurological
data from patients with different allelic variants of
FOXP2, an endeavor that will be essential for under-
standing the role of this gene in human cognition.
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